Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE vs EPINEPHRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine, an amide-type local anesthetic, stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Epinephrine acts as a vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing local blood flow and prolonging anesthetic effect.
Epinephrine is a direct-acting sympathomimetic amine that stimulates alpha-1, alpha-2, beta-1, beta-2, and beta-3 adrenergic receptors. Its effects include vasoconstriction (alpha-1), bronchodilation (beta-2), increased heart rate and contractility (beta-1), and relaxation of uterine and bladder smooth muscle.
Local anesthesia for infiltration, nerve block, and epidural anesthesia,Dental anesthesia,Surgical procedures requiring local anesthesia
Emergency treatment of anaphylactic reactions,Acute asthma exacerbation (subcutaneous injection),Cardiac arrest (ACLS protocol, intravenous or intraosseous),Treatment of hypotension associated with septic shock (off-label),Treatment of severe allergic reactions (epinephrine auto-injector),Local hemostatic agent (diluted solution, off-label)
1-2 m L of 2% lidocaine (20-40 mg) with epinephrine 1:100,000 (0.01-0.02 mg epinephrine) injected locally; maximum single dose 7 mg/kg lidocaine (7 m L/kg of 0.1% solution equivalent).
0.3-0.5 mg IM (auto-injector or syringe) every 5-15 minutes as needed for anaphylaxis; IV: 0.1-0.5 mg (1-10 mcg/min infusion) for hemodynamic support.
Alphacaine: 1.5-2 hours; epinephrine: 2-3 minutes. Clinical context: The duration of local anesthesia is prolonged by epinephrine-induced vasoconstriction, not by the half-life of alphacaine.
1-2 minutes (intravenous); clinical effect termination primarily due to rapid uptake and metabolism, not elimination half-life.
Lidocaine is primarily metabolized in the liver via CYP3A4 and CYP1A2 to monoethylglycinexylidide (MEGX) and glycinexylidide (GX). Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Epinephrine is metabolized primarily by the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) in the liver, kidneys, and other tissues. The major metabolites are metanephrine, vanillylmandelic acid (VMA), and 3-methoxy-4-hydroxyphenylglycol (MOPEG).
Primarily renal excretion of metabolites and unchanged drug; <5% excreted unchanged in urine. Biliary excretion accounts for a minor fraction.
Primarily hepatic metabolism via catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO); renal excretion of metabolites (inactive) and small fraction (<5%) unchanged.
Alphacaine: 55-65% bound to alpha-1-acid glycoprotein; Epinephrine: minimal binding (15-20% to albumin).
Approximately 50% bound to albumin and alpha-1-acid glycoprotein.
Alphacaine: 1.0-1.5 L/kg, indicating extensive tissue distribution; Epinephrine: 0.2-0.4 L/kg, reflecting rapid uptake into adrenergic tissues.
0.2-0.5 L/kg; reflects distribution into highly perfused tissues.
Intravenous: 100%; Oral: negligible (high first-pass metabolism); Topical: variable (minimal systemic absorption); Local injection: essentially 100% at the site but systemic bioavailability is reduced by epinephrine.
IM: 80-100%, SC: 50-80%, oral: <2% (extensive first-pass metabolism), inhalation: 5-15%.
No specific dose adjustment required; lidocaine clearance minimally affected by renal impairment. Epinephrine use with caution if severe renal impairment due to potential vasoconstrictor effects.
No dose adjustment required for renal impairment; use with caution in severe renal failure due to risk of hypertension and arrhythmias.
Child-Pugh Class A: 60-80% of normal dose; Class B: 40-60% of normal dose; Class C: 20-40% of normal dose; reduce maximum single dose to 70% of standard in severe impairment.
No specific dose adjustment recommended for Child-Pugh class A, B, or C; monitor for exaggerated effects in severe hepatic impairment.
Weight-based: 1-2 mg/kg lidocaine with epinephrine 1:100,000 (0.009-0.018 mg/kg epinephrine) for local infiltration; maximum single dose 4.5 mg/kg lidocaine (0.045 m L/kg of 1% solution).
Anaphylaxis: 0.01 mg/kg IM (max 0.3 mg) every 5-15 minutes; IV: 0.01 mg/kg (0.1-1 mcg/min infusion) titrated to effect.
Start with lowest effective dose (e.g., 0.5-1 m L of 2% lidocaine with epinephrine); reduce maximum single dose to 80% of adult maximum; monitor for cardiovascular effects of epinephrine.
Use lower initial doses (e.g., 0.1-0.3 mg IM) and titrate cautiously due to increased sensitivity and higher risk of adverse effects (tachyarrhythmias, hypertension, myocardial ischemia).
Not for use in obstetrical paracervical block anesthesia due to risk of fetal bradycardia and fetal death.
Epinephrine is not a substitute for immediate medical care in anaphylaxis. Patients should seek emergency medical attention immediately after use.
Risk of systemic toxicity including CNS and cardiac effects,Use with caution in patients with hepatic impairment or severe renal disease,Avoid inadvertent intravascular injection,Epinephrine may cause tachycardia, hypertension, and arrhythmias,Use minimum effective dose,Monitor for signs of methemoglobinemia
Use with caution in patients with cardiovascular disease (e.g., coronary artery disease, hypertension, arrhythmias), hyperthyroidism, diabetes, or pheochromocytoma.,May cause severe hypertension, myocardial ischemia, pulmonary edema, and cardiac arrhythmias.,Avoid extravasation; can cause local tissue necrosis due to alpha-mediated vasoconstriction.,May aggravate narrow-angle glaucoma.,Use with caution in elderly patients and those with cerebrovascular insufficiency.
Hypersensitivity to amide-type anesthetics,Severe hypotension,Concurrent use of MAO inhibitors or tricyclic antidepressants (relative),Shock,Avoid use in areas with poor blood supply
Hypersensitivity to epinephrine or any component of the formulation.,Narrow-angle glaucoma (relative contraindication in emergency situations).,Use during second stage of labor may delay delivery.,Concurrent use with non-selective beta-blockers (e.g., propranolol) may cause severe hypertensive crisis.,Use in patients with hypovolemic shock (except as temporary measure in cardiac arrest).
No significant food interactions. Avoid hot liquids or food until numbness resolves to prevent oral burns.
No specific food interactions. Avoid alcohol as it may worsen hypotension. Caffeine and other sympathomimetics (e.g., weight loss supplements) can potentiate adverse effects.
Pregnancy category C. First trimester: Lidocaine crosses placenta; epinephrine may reduce uterine blood flow. No well-controlled human studies; animal studies show fetal harm at high doses. Second trimester: Similar risks; avoid near cervix to prevent systemic absorption. Third trimester: Placental transfer increases; risk of fetal acidosis, bradycardia, and neurobehavioral depression with high doses.
FDA Pregnancy Category C. Animal studies have shown adverse fetal effects, but no adequate human studies. Epinephrine causes reduced uterine blood flow and fetal hypoxia; risk of fetal harm if used during pregnancy, especially in the second and third trimesters. Avoid in first trimester unless necessary.
Lidocaine and epinephrine are excreted in breast milk in low amounts. Lidocaine M/P ratio ~0.5; epinephrine M/P ratio unknown. Infant dose via milk is ~1-2% of maternal weight-adjusted dose. Risk of neonatal bradycardia or irritability is low with standard doses. Use caution with high doses or repeated administration.
Epinephrine is excreted into breast milk in small amounts. M/P ratio unknown. Oral bioavailability is low, so systemic effects in infant are unlikely. Use with caution, monitor infant for signs of sympathetic stimulation.
Pregnancy increases plasma volume and metabolism; no specific dose adjustments recommended for lidocaine or epinephrine. Use lowest effective dose and concentration to minimize fetal exposure. Avoid intra-arterial injection and use with caution in preeclampsia or compromised placental perfusion.
No specific dose adjustment required for pregnancy. However, increased plasma volume and decreased sensitivity to catecholamines may require higher doses for hemodynamic effect. Use lowest effective dose and titrate to response. Monitor closely for adverse effects.
Alphacaine Hydrochloride w/ Epinephrine is a dental local anesthetic solution containing lidocaine HCl 2% with epinephrine 1:100,000 or 1:50,000. The epinephrine component provides vasoconstriction, prolonging anesthetic duration and reducing systemic absorption. Maximum dose of lidocaine with epinephrine is 7 mg/kg (not to exceed 500 mg). For dental infiltration, use smallest effective volume. Avoid intravascular injection; aspirate before injection. Use caution in patients with severe cardiovascular disease, hypertension, hyperthyroidism, or those on MAOIs or tricyclic antidepressants due to potential for hypertensive crisis. Epinephrine may cause tachycardia or hypertension. Do not use in patients with allergy to amide anesthetics or sulfites (present in some formulations).
Administer epinephrine IM into the vastus lateralis for anaphylaxis; avoid gluteal and IV administration in non-arrest settings due to risk of arrhythmias. Intravenous infusion requires central line and continuous hemodynamic monitoring. Use with extreme caution in patients on non-selective beta-blockers (e.g., propranolol) due to unopposed alpha-mediated hypertension.
This medication is a local anesthetic used to numb a specific area in your mouth for dental procedures.,You may feel a burning sensation during injection, but numbness should set in quickly.,Avoid eating or drinking hot beverages for at least 1 hour after the procedure to prevent burns while numb.,Do not chew on the numb side until sensation returns fully.,If you experience chest pain, palpitations, severe headache, or difficulty breathing, seek emergency medical attention immediately.,Report any signs of allergic reaction such as rash, swelling, or difficulty breathing to your dentist or doctor.,Inform your dentist of all medications you take, especially MAOIs, tricyclic antidepressants, beta-blockers, or thyroid medications.,This medication contains epinephrine, which can raise heart rate and blood pressure.
Seek emergency medical help immediately after using epinephrine auto-injector; symptoms may recur.,Do not delay use if anaphylaxis is suspected; early administration is crucial.,Inject into the outer middle thigh; can be done through clothing if necessary.,Massage injection site for 10 seconds after use to enhance absorption.,Always carry two auto-injectors; a second dose may be needed if symptoms persist.,Store at room temperature; protect from light and do not refrigerate.,Check expiration date regularly and replace as needed.,Train family and caregivers on proper usage.
"Epinephrine, a catecholamine with potent beta-2 adrenergic agonist activity, can antagonize the hypoglycemic effect of tolbutamide, a sulfonylurea insulin secretagogue. By stimulating hepatic gluconeogenesis and glycogenolysis, epinephrine increases blood glucose levels, potentially reducing tolbutamide's efficacy in lowering glucose. This interaction may lead to diminished glycemic control, particularly in diabetic patients under stress or during epinephrine administration for anaphylaxis or hypotension."
"Epinephrine, a non-selective alpha and beta adrenergic agonist, can antagonize the antihypertensive effects of clomipramine, a tricyclic antidepressant (TCA) that inhibits norepinephrine reuptake. Concomitant use may lead to enhanced sympathetic activity, potentially causing severe hypertension, tachycardia, and increased risk of arrhythmias. This interaction is particularly concerning during local anesthetic procedures involving epinephrine or systemic administration in patients on clomipramine."
"Epinephrine, a sympathomimetic amine with potent beta-2 adrenergic agonist activity, can directly antagonize the insulin-sensitizing effects of pioglitazone by stimulating glycogenolysis and gluconeogenesis, leading to increased hepatic glucose output and reduced peripheral glucose uptake. This functional antagonism may result in a significant elevation of blood glucose levels, thereby diminishing the therapeutic efficacy of pioglitazone in managing type 2 diabetes. In diabetic patients, the interaction may precipitate acute hyperglycemia, requiring dosage adjustments or alternative therapeutic strategies."
"Epinephrine, a catecholamine with potent beta-2 adrenergic agonist activity, can antagonize the hypoglycemic effect of tolbutamide, a sulfonylurea insulin secretagogue. By stimulating hepatic gluconeogenesis and glycogenolysis, epinephrine increases blood glucose levels, potentially reducing tolbutamide's efficacy in lowering glucose. This interaction may lead to diminished glycemic control, particularly in diabetic patients under stress or during epinephrine administration for anaphylaxis or hypotension."
"Epinephrine, a non-selective alpha and beta adrenergic agonist, can antagonize the antihypertensive effects of clomipramine, a tricyclic antidepressant (TCA) that inhibits norepinephrine reuptake. Concomitant use may lead to enhanced sympathetic activity, potentially causing severe hypertension, tachycardia, and increased risk of arrhythmias. This interaction is particularly concerning during local anesthetic procedures involving epinephrine or systemic administration in patients on clomipramine."
"Epinephrine, a sympathomimetic amine with potent beta-2 adrenergic agonist activity, can directly antagonize the insulin-sensitizing effects of pioglitazone by stimulating glycogenolysis and gluconeogenesis, leading to increased hepatic glucose output and reduced peripheral glucose uptake. This functional antagonism may result in a significant elevation of blood glucose levels, thereby diminishing the therapeutic efficacy of pioglitazone in managing type 2 diabetes. In diabetic patients, the interaction may precipitate acute hyperglycemia, requiring dosage adjustments or alternative therapeutic strategies."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE vs EPINEPHRINE, answered by our medical review team.
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is a Alpha/Beta Agonist that works by Lidocaine, an amide-type local anesthetic, stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Epinephrine acts as a vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing local blood flow and prolonging anesthetic effect.. EPINEPHRINE is a Alpha/Beta Agonist that works by Epinephrine is a direct-acting sympathomimetic amine that stimulates alpha-1, alpha-2, beta-1, beta-2, and beta-3 adrenergic receptors. Its effects include vasoconstriction (alpha-1), bronchodilation (beta-2), increased heart rate and contractility (beta-1), and relaxation of uterine and bladder smooth muscle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE and EPINEPHRINE depend on the specific clinical indication. These are both Alpha/Beta Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is: 1-2 m L of 2% lidocaine (20-40 mg) with epinephrine 1:100,000 (0.01-0.02 mg epinephrine) injected locally; maximum single dose 7 mg/kg lidocaine (7 m L/kg of 0.1% solution equivalent).. The standard adult dose of EPINEPHRINE is: 0.3-0.5 mg IM (auto-injector or syringe) every 5-15 minutes as needed for anaphylaxis; IV: 0.1-0.5 mg (1-10 mcg/min infusion) for hemodynamic support.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE and EPINEPHRINE. Epinephrine, a catecholamine with potent beta-2 adrenergic agonist activity, can antagonize the hypoglycemic effect of tolbutamide, a sulfonylurea insulin secretagogue. By stimulating hepatic gluconeogenesis and glycogenolysis, epinephrine increases blood glucose levels, potentially reducing tolbutamide's efficacy in lowering glucose. This interaction may lead to diminished glycemic control, particularly in diabetic patients under stress or during epinephrine administration for anaphylaxis or hypotension. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is classified as Category A/B. Pregnancy category C. First trimester: Lidocaine crosses placenta; epinephrine may reduce uterine blood flow. No well-controlled human studies; animal studies show fetal harm at hi. EPINEPHRINE is classified as Category A/B. FDA Pregnancy Category C. Animal studies have shown adverse fetal effects, but no adequate human studies. Epinephrine causes reduced uterine blood flow and fetal hypoxia; risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.